Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)
The Agencia Espanola de Medicamentos y Productos Sanitarios (Spanish Agency of Medicines and Medical Devices), commonly known as AEMPS, is an autonomous public agency of the Government of Spain. It is not a private company but rather Spain's national regulatory authority responsible for guaranteeing the quality, safety, efficacy, and correct information of all medicines and medical devices, from their initial research phase through their entire lifecycle on the market.
Attached to the Ministry of Health (Ministerio de Sanidad), AEMPS functions as the central guarantor of public and animal health in relation to regulated health products. Its "products and services" are not commercial goods but are instead critical regulatory functions, public information services, and scientific evaluations that protect citizens and facilitate innovation within a safe framework.
Continue…The entity's responsibilities cover the entire spectrum of therapeutic products, which can be broken down into several key areas of activity.
Core Functions and Services
AEMPS's activities are centered on scientific-technical evaluation, authorization, inspection, and continuous surveillance.
1. Medicines for Human Use
This is the largest and most critical area of AEMPS's responsibility, covering the entire lifecycle of a pharmaceutical drug.
- Marketing Authorisation: AEMPS is the body that evaluates and authorizes a medicine before it can be legally sold in Spain. This includes managing different EU procedures:
- National Procedure: For products intended only for the Spanish market.
- Mutual Recognition & Decentralised Procedures: Collaborative processes where AEMPS works with other EU member states to approve medicines simultaneously across multiple countries.
- Centralised Procedure: AEMPS acts as Spain's representative, participating in the scientific evaluations led by the European Medicines Agency (EMA) for drugs intended for the entire EU market.
- Clinical Research Authorisation: AEMPS evaluates and authorises every clinical trial involving medicinal products that is to be conducted in Spain, ensuring that the study design is scientifically sound and that the rights and safety of trial participants are protected.
- Pharmacovigilance: This is the continuous safety monitoring of medicines after they are on the market. AEMPS manages the Spanish Pharmacovigilance System (SEFV-H), which collects, analyzes, and evaluates reports of suspected adverse drug reactions submitted by healthcare professionals and citizens. If a new risk is identified, AEMPS issues public safety alerts and can take regulatory action, such as updating the product information (leaflet) or, in rare cases, suspending or withdrawing the medicine.
- Information Services: A key public service is the management of CIMA (Centro de Informaci?n online de Medicamentos de la AEMPS). This is a comprehensive, free online database providing the official information (summary of product characteristics and patient leaflet) for every medicine authorized in Spain. AEMPS also manages and communicates on medicine supply shortages.
2. Medical Devices ("Productos Sanitarios")
AEMPS regulates all medical devices, from simple items like tongue depressors and syringes to complex technologies like pacemakers, breast implants, and AI-driven diagnostic software.
* Market Surveillance: Unlike medicines, most devices do not require pre-approval from AEMPS but are certified with a CE Mark by a Notified Body. AEMPS's role is therefore focused on market control, ensuring products sold in Spain comply with safety standards and investigating non-compliant or falsified devices.
* Vigilance: Similar to pharmacovigilance, this system monitors adverse incidents related to the use of medical devices. AEMPS collects these reports from healthcare professionals and the public to identify risks and coordinate corrective actions (like product recalls).
* Authorisation of Clinical Investigations: Any clinical study required to demonstrate the safety or performance of a medical device must be authorized by AEMPS before it can begin in Spain.
3. Medicines for Veterinary Use
AEMPS performs the identical regulatory functions for medicines intended for animals as it does for human medicines. This includes marketing authorisation, oversight of clinical trials, and a dedicated veterinary pharmacovigilance system to monitor adverse events in animals and potential safety issues for humans related to residues in food products. It maintains a separate database for this, CIMAvet.
4. Cosmetics, Biocides, and Personal Care Products
AEMPS is also the competent authority for the safety and surveillance of cosmetics, tattoos/permanent makeup inks, biocides (like hand sanitizers and disinfectants), and personal care products.
* Market Supervision: It ensures these products comply with EU and Spanish regulations regarding labeling, ingredients, and claims.
* Cosmetovigilance: It manages a system for reporting undesirable effects caused by cosmetics.
* Registration and Control: It manages the national registries for companies performing activities with these products and controls their import from non-EU countries.
5. Inspection and Control
AEMPS has a powerful enforcement arm to ensure industry-wide compliance.
* Laboratory Authorisation: It inspects and authorises all pharmaceutical laboratories (manufacturers and importers) in Spain, ensuring they comply with Good Manufacturing Practices (GMP).
* Control of Narcotic and Psychotropic Substances: It manages the medical and scientific use of controlled substances, alloacating quotas and overseeing their distribution.
* Combating Falsified Medicines: AEMPS actively works with law enforcement (like the Guardia Civil) to investigate and shut down illegal websites and supply chains for falsified, unapproved, or counterfeit medicines.
